Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michio Sata

Showing results (261-270 of 416) with videos related to

Pageof 42
Sort By:
Oncology Reports|May 17, 2011
Quantitative analysis of colorectal mucosal lesions by autofluorescence endoscopy: discrimination of carcinomas from other lesionsKeiko Arita, Keiichi Mitsuyama, Hiroshi Kawano, et al.
Archives of Virology|July 2, 2008
A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapyKei Ogata, Takahito Kashiwagi, Jun Iwahashi, et al.
Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society|December 24, 2010
Direct cholangioscopy using a double-balloon enteroscope: choledochojejunostomy with intraductal biliary carcinomaYoshinobu Okabe, Kotaro Kuwaki, Hiroshi Kawano, et al.
Journal of Gastroenterology|April 14, 2010
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosisKiwamu Okita, Isao Sakaida, Mitsuru Okada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 17, 2010
Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)Shigeki Arii, Michio Sata, Michiie Sakamoto, et al.
Oncology Reports|April 30, 2010
The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinomaSakae Nagaoka, Takafumi Yoshida, Junji Akiyoshi, et al.
Journal of Medical Virology|November 25, 2003
Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapyReiichiro Kuwahara, Ryukichi Kumashiro, Shiro Murashima, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 2, 2007
Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosisHiroyuki Koga, Tatsuya Ide, Kazuhiko Oho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2012
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in miceKinya Inoue, Takuji Torimura, Toru Nakamura, et al.
Digestive Diseases and Sciences|July 12, 2008
Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBVReiichiro Kuwahara, Ryukichi Kumashiro, Tatsuya Ide, et al.
Pageof 42

Showing results (261-270 of 416) with videos related to

Sort By:
Pageof 42
Oncology Reports|May 17, 2011
Quantitative analysis of colorectal mucosal lesions by autofluorescence endoscopy: discrimination of carcinomas from other lesionsKeiko Arita, Keiichi Mitsuyama, Hiroshi Kawano, et al.
Archives of Virology|July 2, 2008
A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapyKei Ogata, Takahito Kashiwagi, Jun Iwahashi, et al.
Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society|December 24, 2010
Direct cholangioscopy using a double-balloon enteroscope: choledochojejunostomy with intraductal biliary carcinomaYoshinobu Okabe, Kotaro Kuwaki, Hiroshi Kawano, et al.
Journal of Gastroenterology|April 14, 2010
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosisKiwamu Okita, Isao Sakaida, Mitsuru Okada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 17, 2010
Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)Shigeki Arii, Michio Sata, Michiie Sakamoto, et al.
Oncology Reports|April 30, 2010
The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinomaSakae Nagaoka, Takafumi Yoshida, Junji Akiyoshi, et al.
Journal of Medical Virology|November 25, 2003
Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapyReiichiro Kuwahara, Ryukichi Kumashiro, Shiro Murashima, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 2, 2007
Lamivudine treatment-related morphological changes of esophageal varices in patients with liver cirrhosisHiroyuki Koga, Tatsuya Ide, Kazuhiko Oho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2012
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in miceKinya Inoue, Takuji Torimura, Toru Nakamura, et al.
Digestive Diseases and Sciences|July 12, 2008
Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBVReiichiro Kuwahara, Ryukichi Kumashiro, Tatsuya Ide, et al.
Pageof 42